J&J to build $2b facility in North Carolina to make future products
HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.
Drugs
Health
Pharma
Climate
Health
Pharma
ADNOC to buy Germany’s chemical producer Covestro for $13 billion
The Abu Dhabi National Oil Company, ADNOC, the state-owned oil company of the United Arab Emirates, will buy Germany’s chemicals maker Covestro AG.
Drugs
Health
Pharma
AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.
Drugs
Health
Pharma
Marburg virus disease kills 8 people in Rwanda, 26 others confirmed
Eight people have died in Rwanda due to Marburg virus disease and 26 others were confirmed to be infected by the illness —.
Drugs
Health
Pharma
Kezar Life Sciences halts mid-stage lupus nephritis trial after four people die
Kezar Life Sciences Inc., a US-based biotechnology company, has stopped a trial in patients with a type of kidney disease after four people.
Drugs
Health
Pharma
Roche arm to buy breast cancer portfolio from Regor for $850 million
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.
Drugs
Health
Pharma
Henlius, Organon trial drug meets goal of an absence of breast cancer
Shanghai Henlius Biotech, Inc., and US-based Organon & Co. announced their end-stage trial for investigational breast cancer had met its main goal of.
Drugs
Health
Pharma
Cambridge Univ. researchers develop ‘jelly batteries’ for devices, implants
Cambridge University researchers, taking inspiration from electric eels, have developed stretchable ‘jelly batteries’ that could be used to deliver drugs or treat conditions.
Drugs
Health
Pharma
Regeneron-Sanofi’s drug for lung disease gets US approval
Regeneron Pharmaceuticals and Sanofi’s drug, Dupixent, got the US regulator’s approval to treat patients with chronic obstructive pulmonary disease.
Drugs
Health
Pharma
FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.